Autres langues Chugai Pharmaceutical Co., Ltd

Actions

4519

JP3519400000

Temps Différé Japan Exchange Autres places de cotation 02:14:19 26/04/2024			Varia. 5j.	Varia. 1 janv.
4 813 ^JPY	-0,97 %		-1,99 %	-9,72 %

25/04	Roche, la société mère de Chugai Pharmaceutical, enregistre une baisse des ventes au premier trimestre ; l'action chute de 5%.	MT
24/04	Le bénéfice de Chugai Pharmaceutical en légère hausse au premier trimestre	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Chugai Announces 2024 1st Quarter Results	25/04
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	25/04
Chugai Pharmaceutical's Profit Slightly Up in Q1	24/04
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)	24/04
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024	24/04
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	15/04
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	10/04
MÄRKTE ASIEN/Uneinheitlich vor US-Inflationsdaten - Hongkong deutlich im Plus	10/04
Japan's Nikkei slips on caution ahead of US inflation data	10/04
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	29/03
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	28/03
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	28/03
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	27/03
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	27/03
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	27/03
Roche's Chugai Wins Japanese Approval for Piasky Injection	27/03
Chugai Pharmaceutical : Finance Report (Jan-Dec 2023) (Posted on March 28)	25/03
MIDDAY BRIEFING - Unternehmen und Märkte	22/03
Argenx flink in de lift	21/03
Roche-Tochter Chugai erreicht in Phase-III-Studie mit Enspryng Ziele nicht	21/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Chugai Pharmaceutical Co., Ltd

Actions

4519

JP3519400000

Autres langues

Filtres